Giovanni Mansueto

Learn More
BACKGROUND To evaluate the therapeutic strategies commonly employed in the clinic for the management of brain metastases (BMs) and to correlate disease outcome with type of treatment and therapeutic resources available at the treating center. METHODS Four Cancer centres participated to the survey. Data were collected through a questionnaire filled in by(More)
Lung cancer is the most common cause of death in oncology patients worldwide (1). Cisplatin-based chemotherapy is the gold standard for treatment in lung cancer patients with locally advanced or metastatic disease (2). Completion of all planned chemotherapy cycles is essential to give patients the maximum chance of treatment success (2,3).(More)
BACKGROUND For patients with stage IV nonsmall cell lung cancer (NSCLC) who present with brain metastasis (BMs), standard platinum-based chemotherapy regimens have challenged the role of up-front whole-brain radiotherapy (WBRT). METHODS In this survey, the authors analyzed the decision tree by which 6 oncologic centers guided the pattern of care in an(More)
The combination of a neurokinin-1 receptor antagonist, dexamethasone, and a 5-HT3 receptor antagonist is currently the standard antiemetic treatment in patients receiving cisplatin-based high emetogenic chemotherapy (HEC). The aim of this study was to evaluate the efficacy of a combination of palonosetron, a unique second-generation 5-HT3 receptor(More)
PURPOSE The selection of effective schedules of treatment for metastatic non-small cell lung cancer still remains a challenge for the oncologist. The present multicentric phase II study was designed in order to investigate the activity and safety of the combination of weekly paclitaxel and celecoxib as second-line treatment for non-small cell lung cancer.(More)
BACKGROUND AND OBJECTIVE In the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with Dukes' C colorectal cancer. We used the X-ACT results to determine the cost(More)
AIM To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS We designed a single-arm prospective, multicentre, open-label phase II study to evaluate the combination of erlotinib (100 mg/d, orally) and weekly FDR-Gem (1000 mg/m(2), infused at 10(More)